Skip to main content
editor@theusajournals.com | Oscar Publishing Services Journal Home

International Journal of Medical Sciences And Clinical Research

Peer Reviewed | Open Access | E-ISSN: 2771-2265
Published Article

The Role of Myo-Inositol in Complex Treatment in Correction of Insulin Resistance in Patients with Acne

The Role of Myo-Inositol in Complex Treatment in Correction of Insulin Resistance in Patients with Acne

  • Mikamol Mukhtor Ugli Mirvasidov
    Assistant Lecturer, Department of Dermatovenereology and Cosmetology No. 1, Tashkent State Medical University, Uzbekistan
insulin resistance myo-inositol Acne vulgaris

Acne vulgaris is one of the most prevalent chronic inflammatory skin disorders affecting adolescents and adults worldwide. Recent studies have demonstrated a close relationship between insulin resistance, hyperinsulinemia, androgen excess, and the pathogenesis of acne. Insulin resistance contributes to increased production of insulin-like growth factor-1 (IGF-1), stimulation of sebaceous gland activity, follicular hyperkeratinization, and inflammatory responses. Myo-inositol, a naturally occurring carbocyclic sugar and an important intracellular signaling molecule, has gained significant attention as a therapeutic agent capable of improving insulin sensitivity and metabolic parameters. This review analyzes the role of myo-inositol in the complex treatment of acne patients with insulin resistance and discusses its potential mechanisms of action, clinical benefits, and therapeutic perspectives.

Nestler J.E., Jakubowicz D.J. Myo-inositol in the treatment of polycystic ovary syndrome. Current Opinion in Obstetrics and Gynecology. 2020;32(4):242–248.

D'Anna R., Scilipoti A., Giordano D. Myo-inositol supplementation and insulin resistance: clinical implications. Gynecological Endocrinology. 2021;37(6):501–507.

Del Prete M., Mauriello M.C., Faggiano A. Insulin resistance and acne: a systematic review. Journal of Endocrinological Investigation. 2022;45(3):419–429.

Melnik B.C. Linking diet to acne metabolomics, inflammation, and comedogenesis. Clinical Cosmetic and Investigational Dermatology. 2020;13:371–388.

Zaenglein A.L., Pathy A.L., Schlosser B.J. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2024;90(2):305–329.

Diamanti-Kandarakis E., Paterakis T., Kandarakis H. The role of inositols in endocrine and metabolic disorders. International Journal of Endocrinology. 2023;2023:1–12.

Bhate K., Williams H.C. Epidemiology of acne vulgaris. British Journal of Dermatology. 2021;184(4):594–601.

Melnik B.C. Acne vulgaris and insulin resistance. Experimental Dermatology. 2022;31(8):1141–1152.

Unfer V., Facchinetti F., Orrù B. Myo-inositol effects in insulin-resistant conditions. European Review for Medical and Pharmacological Sciences. 2023;27(5):1824–1835.

Thiboutot D., Gollnick H., Bettoli V. New insights into acne pathogenesis and treatment. Dermatology Reports. 2024;16(1):45–57.